REFERENCES
- Hale, G., Bright, S., Chumbley, G., Hoang, T., Metcalf, D., Munro, A., et al. (1983) "Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement", Blood, 62, 873–882.
- Hale, G., Xia, M., Tighe, H., Dyer, M. and Waldmann, H. (1990) "The CAMPATH-1 antigen (CDw52)", Tissue Antigens, 35, 118 — 127.
- Ginaldi, L., De Martinis, M., Matutes, E., Farahat, N., Morilla, R., Dyer, M., et al. (1998) "Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H", Leukemia Research, 22, 185–191.
- Salisbury, J., Rapson, N., Codd, J., Rogers, M. and Nethersell, A. (1994) "Immunohistochemical analysis of CDw52 antigen expres-sion in non-Hodgkin's lymphomas", Journal of Clinical Pathology, 47, 313 — 317.
- Pawson, R., Dyer, M., Barge, R., Matutes, E., Thornton, P., Emmett, E., et al. (1997) "Treatment of T-cell prolymphocytic leukemia with human CD52 antibody", Journal of Clinical Oncology, 15, 2667–2672.
- Dearden, C., Matutes, E., Cazin, B., Tjonnfjord, G., Parreira, A., Nomdedeu, B., et al. (2001) "High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H", Blood, 98, 1721–1726.
- Keating, M., Cazin, B., Coutre, S., Birhiray, R., Kovacsovics, T., Langer, W., et al. (2002) "Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed", Journal of Clinical Oncology, 20, 205— 213.
- Osterborg, A., Dyer, M., Bunjes, D., Pangalis, G., Bastion, Y., Catovsky, D., et al. (1997) "Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H treatment in Chronic Lymphocytic Leukemia", Journal of Clinical Oncology, 15, 1567 — 1574.
- Bowen, A., Zomas, A., Emmett, E., Matutes, E., Dyer, M. and Catovsky, D. (1997) "Subcutaneous CAMPATH-1H in fludara-bine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia", British Journal of Haematology, 96, 617 — 619.
- Dyer, M., Kelsey, S., Mackay, H., Emmett, E., Thornton, P., Hale, G., et al. (1997) "In vivo 'purging' of residual disease in CLL with Campath-1H", British Journal of Haematology, 97, 669 — 672.
- McCune, S., Gockerman, J., Moore, J., Decastro, C., Bass, A., Chao, N., et al. (2002) "Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia", Leukemia Lymphoma, 43, 1007 — 1111.
- Hale, G., Dyer, M., Clark, M., Phillips, J., Marcus, R., Riechmann, L., et al. (1988) "Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H", Lancet, 2, 1394 — 1399.
- Dyer, M., Hale, G., Hayhoe, F. and Waldmann, H. (1989) "Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype", Blood, 73, 1431–1439.
- Keating, M., Flinn, I., JaM, V., Binet, J., Hillmen, P., Byrd, J., et al. (2002) "Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study", Blood, 99, 3554–3561.
- Lundin, J., Osterborg, A., Brittinger, G., Crowther, D., Dombret, H., Engert, A., et al. (1998) "CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lym-phomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lym-phoma", Journal of Clinical Oncology, 16(10), 3257–3263.
- Lundin, J., Kimby, E., Bjorkholm, M., Broliden, P., Celsing, F., Hjalmar, V., et al. (2002) "Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)", Blood, 100, 768–773.